The guidance, which was published after the European market closed on 3 February, was punished by investors at market open.

Relay Therapeutics has received the FDA BTD for zovegalisib, along with fulvestrant, for HR+/HER2- advanced breast cancer treatment.

CEPI and Samsung Biologics have partnered in an outbreak-ready vaccine manufacturing partnership to enhance the preparedness of global vaccine production for pandemic threats and future epidemic.

Despite posting strong results in the final quarter of 2025, MSD (Merck & Co) has cut its 2026 guidance more than analysts had expected as the drugmaker prepares for the loss of exclusivity of several ...

As FY25 results reveal a mixed year for Pfizer, the company is looking to turn its fortunes around with newly acquired Metsera obesity assets.

SanegeneBio has entered into a $1.5bn global licensing agreement with Genentech, part of the Roche Group, for one of its RNAi ...

Recent reports of Nipah virus (NiV) infections in West Bengal, India, have reignited global concern, prompting public health ...

Historically a steel production hub, Lehigh Valley will now help manufacture Lilly’s weight loss drug hopeful retatrutide.

Kyowa Kirin will now file for rocatinlimab’s US approval in atopic dermatitis (AD), which was once Amgen’s most late-stage pipeline candidate.

Sino Biological US, Inc., a global leader in recombinant proteins, antibodies, and CRO services, will be featured on Inside ...

The California Institute for Regenerative Medicine has approved the RAPID funding programme, setting aside $100m over two ...

AstraZeneca's investment coincides with China’s burgeoning presence in the pharmaceutical industry, driven by an uptick in ...